Osajin
Based on 1 Customer Validation
Osajin is the major bioactive isoflavone present in the fruit of Maclura pomifera with antitumor, antioxidant and anti-inflammatory activities.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.36%
- No. CAS: 482-53-1
- Fòrmula: C25H24O5
- Peso molecular:404.46
-
Almacenamiento:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
IC50 & Target
Apoptosis[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ACHN | GI50 |
12.13 μM
Compound: 1, osajin
|
Growth inhibition of human ACHN cells after 21 hrs by MTT assay
Growth inhibition of human ACHN cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| BMDM | IC50 |
12 μg/mL
Compound: 133
|
Antiinflammatory activity in LPS-stimulated mouse BMDM cells assessed as inhibition of NF-kappaB signalling pathway incubated for 3 hrs by Western blot analysis
Antiinflammatory activity in LPS-stimulated mouse BMDM cells assessed as inhibition of NF-kappaB signalling pathway incubated for 3 hrs by Western blot analysis
|
[PMID: 37683361] |
| HCT-15 | GI50 |
9.65 μM
Compound: 1, osajin
|
Growth inhibition of human HCT15 cells after 21 hrs by MTT assay
Growth inhibition of human HCT15 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| HeLa | IC50 |
6.53 μM
Compound: 1, osajin
|
Inhibition of HDAC in HeLa cells
Inhibition of HDAC in HeLa cells
|
[PMID: 17662606] |
| Hepatocyte | GI50 |
>500 μM
Compound: 1, osajin
|
Growth inhibition of human hepatocytes after 21 hrs by MTT assay
Growth inhibition of human hepatocytes after 21 hrs by MTT assay
|
[PMID: 17662606] |
| LOX IMVI | GI50 |
10.98 μM
Compound: 1, osajin
|
Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay
Growth inhibition of human LOX-IMVI cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| MDA-MB-231 | GI50 |
11.34 μM
Compound: 1, osajin
|
Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| NCI-H23 | GI50 |
11.97 μM
Compound: 1, osajin
|
Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay
Growth inhibition of human NCI-H23 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| PC-3 | GI50 |
12.32 μM
Compound: 1, osajin
|
Growth inhibition of human PC3 cells after 21 hrs by MTT assay
Growth inhibition of human PC3 cells after 21 hrs by MTT assay
|
[PMID: 17662606] |
| RAW264.7 | IC50 |
7.2 μg/mL
Compound: 133
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS mRNA expression
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced iNOS mRNA expression
|
[PMID: 37683361] |
| Vero | CC50 |
11.44 μM
Compound: Osajin
|
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
|
10.1101/2020.03.20.999730 |
| Vero | IC50 |
3.87 μM
Compound: Osajin
|
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
|
10.1101/2020.03.20.999730 |
In Vitro
Osajin significantly decreases the viability of human NPC cells (TW076, CG1 and TW04 cells) in a dose-dependent manner. Osajin induces apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress[1]. Osajin exhibits growth inhibitory activity on six human cancer cell lines, including kidney, lung, prostate, breast, melanoma and colon cancer cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 482-53-1
-
Appearance Solid
-
Peso molecular 404.46
-
Fòrmula C25H24O5
-
Color White to off-white
-
SMILES
O=C1C2=C(O)C(C/C=C(C)\C)=C3C(C=CC(C)(C)O3)=C2OC=C1C4=CC=C(O)C=C4
-
Synonyms
CID 95168; NSC 21565
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvente y solubilidad
In Vitro:
DMSO : 50 mg/mL (123.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.18 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (458 KB)
- English - EN (458 KB)
- Français - FR (458 KB)
- Deutsch - DE (458 KB)
- Norwegian - NO (458 KB)
- Español - ES (458 KB)
- Swedish - SV (458 KB)
- Italian - IT (458 KB)
- Korean - KR (458 KB)
- Portuguese - PT (458 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Huang TT, et al. Activation of multiple apoptotic pathways in human nasopharyngeal carcinoma cells by the prenylated isoflavone, osajin. PLoS One. 2011 Apr 12;6(4):e18308. [Content Brief]
[2]. Son IH, et al. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4753-5. [Content Brief]
[3]. Florian T, et al. Effects of prenylated isoflavones osajin and pomiferin in premedication on heart ischemia-reperfusion. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):93-100. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4724 mL | 12.3622 mL | 24.7243 mL | 61.8108 mL |
| 5 mM | 0.4945 mL | 2.4724 mL | 4.9449 mL | 12.3622 mL | |
| 10 mM | 0.2472 mL | 1.2362 mL | 2.4724 mL | 6.1811 mL | |
| 15 mM | 0.1648 mL | 0.8241 mL | 1.6483 mL | 4.1207 mL | |
| 20 mM | 0.1236 mL | 0.6181 mL | 1.2362 mL | 3.0905 mL | |
| 25 mM | 0.0989 mL | 0.4945 mL | 0.9890 mL | 2.4724 mL | |
| 30 mM | 0.0824 mL | 0.4121 mL | 0.8241 mL | 2.0604 mL | |
| 40 mM | 0.0618 mL | 0.3091 mL | 0.6181 mL | 1.5453 mL | |
| 50 mM | 0.0494 mL | 0.2472 mL | 0.4945 mL | 1.2362 mL | |
| 60 mM | 0.0412 mL | 0.2060 mL | 0.4121 mL | 1.0302 mL | |
| 80 mM | 0.0309 mL | 0.1545 mL | 0.3091 mL | 0.7726 mL | |
| 100 mM | 0.0247 mL | 0.1236 mL | 0.2472 mL | 0.6181 mL |
Osajin Related Classifications
HY-N3125 Related Classifications
Powered by Bioz